BTIG reiterates Buy on Nektar Therapeutics, $178 target
BTIG reiterated a Buy rating on Nektar Therapeutics and set a $178 price target, implying 167.1% upside versus the Sep 15 close of $66.64.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.